Is NCT04992624 recruiting in Ann Arbor, MI?

Yes, NCT04992624 is currently recruiting participants at its Ann Arbor, MI location. This osteoarthritis, knee clinical trial is actively enrolling qualified participants.

How do I join the osteoarthritis, knee clinical trial in Ann Arbor?

To join this clinical trial in Ann Arbor, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Ann Arbor clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Osteoarthritis, Knee Clinical Trial in Ann Arbor, MI

About This Osteoarthritis, Knee Study in Ann Arbor

This clinical trial is being done to better understand how daily treatment with Tetrahydrocannabinol (THC), Cannabidiol (CBD), or the combination of CBD plus THC affects knee osteoarthritis pain and other related symptoms. Consented participants will have a screening period and visit (up to 30 days to treatment start). If participants pass the screening phase, they will be randomly assigned to take one of the investigational study drugs. For this study, participants will not know when or if they are taking CBD, THC, THC plus CBD, and when or if taking placebo. Clinical pain will be assessed at multiple times throughout the study, and eligibility will be re-assessed at two weeks into the treatment period. It is possible that subjects will not be able to participate in the study after 14 days of of treatment. The treatment period will take approximately 16 weeks and then a follow-up period for approximately 2 weeks. In addition to treatment, participants will have clinical assessments, blood draws, questionnaires, daily pain diaries, sensory testing, as well as have functional connectivity magnetic resonance imaging (fcMRI).

Sponsor: Steven E Harte, PhD

Who Can Participate

Inclusion Criteria

Ability to read and speak English to allow for written informed consent, phenotyping, and patient-reported outcomes measures

Willingness to participate in a drug intervention trial

Diagnosis of osteoarthritis (OA) of the knee by a medical provider (confirmed by checking medical records)

Chronic knee pain, defined as moderate to severe knee pain for ≥ 6-month duration

No use of cannabis or CBD in the past in the month prior to study enrollment as per self-report

Fibromyalgia (FM) Survey Criteria score available. The questionnaire will be assessed by the research team for scoring. We will recruit enough patients to satisfy the spectrum of FM scores in four quartiles based on our previously existing data. Once a quartile is filled (approximately 40 patients enrolled), then we will not include more people from that quartile.

Self-reported normal visual acuity or correctable (with corrective lenses- glasses or contacts) to at least 20/40 for reading instructions in the MRI and visual sensitivity testing

No contraindications to magnetic resonance imaging (MRI) (for example (e.g.), metal implants)

Able to lie still on their back for 1-1.5 hours during MRI

Willingness to refrain from pain medications such as non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen for 12 hours prior to neuroimaging and Quantitative Sensory Testing (QST)

Willingness to refrain from alcohol and nicotine before QST and neuroimaging (alcohol and nicotine consumption is allowed after testing is completed)

Willingness to refrain from physical activity or exercise that would cause significant muscle and/or joint soreness for 48 hours prior to testing (routine exercise or activity that does not lead to soreness is acceptable)

Willingness to maintain a stable treatment regimen for chronic knee OA pain during the clinical trial (e.g., not initiating a new course of physical therapy)

No use of adjunctive pain medications or stable chronic daily use of adjunctive pain medications (excluding opioids)

Willingness to avoid grapefruit juice or food products for the duration of the study;

Females of reproductive potential must agree to use acceptable birth control from the screening visit and until the completion study drug administration. Sexually active male participants and/or their female partners must agree to use effective contraception during study drug treatment of the male participant. Male participants may also agree not to donate sperm during study drug treatment

Exclusion Criteria

Individuals who are actively applying for or in litigation for compensation or disability and other aspects associated with potential secondary gain per self-report

Inability to provide written informed consent

Previous total knee arthroplasty

Planned total knee arthroplasty within the time frame of the study

Severe physical impairment (e.g., blindness, deafness, paraplegia)

Co-morbid medical conditions that may significantly impair physical functional status (e.g., history of non-skin malignancy, or autoimmune disorder)

Use of cannabis or CBD in the past month per self-report and/or drug screen

Current opioid use (excepting tramadol) per self-report and/or drug screen

Current valproate, clobazam, or warfarin use per self-report or medical records

Current use of moderate or strong inhibitors of cytochrome p450 (CYP) enzymes CYP3A4 and CYP2C19, strong inducers of CYP3A4 or CYP2C19, moderate or strong inhibitors/inducers of CYP2C9, and narrow therapeutic index drugs (e.g., cyclosporine, amphotericin B). Participants will also not be allowed to start using these drugs during the study period if they wish to stay in the study

Self-reported allergies to sesame oil or cannabis/cannabinoids

Self-reported medical or psychiatric conditions that in the judgment of study personnel would preclude participation in this study (e.g., schizophrenia, malignancy, psychosis, suicidal ideation, history of substance abuse; note that stable anxiety and depression are not exclusions)

Pregnant or nursing

Liver failure

Self-reported liver cirrhosis

Active diagnosis or current symptoms of hepatitis by self-report

Self-reported uncontrolled diabetes

Blood pressure at screening above 180 systolic and/or 120 diastolic

Resting heart rate at screening less than 50 beats per minute (bpm) or greater than 100 bpm;

Elevated liver enzymes and bilirubin (measured via blood test at screening):

Serum total bilirubin ≥ 2.5 milligrams per deciliter (mg/dL); or,

Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) ≥ 3x upper limit normal (ULN); or,

Alkaline phosphatase ≥ 2 times ULN

Severe cardiovascular disease (examples: history of myocardial infarction, unstable angina, severe coronary artery disease, congestive heart failure, or severe valvular abnormalities) that is self-reported by patient or by medical record

Severe claustrophobia precluding MRI

Unable to fit in or lie comfortably in MRI

Diagnosed peripheral neuropathy

Diagnosed or self-reported epilepsy or history of seizures

Current head injury or history of head injury (e.g., traumatic brain injury)

Any impairment, activity, behavior, or situation that in the judgment of the study team would prevent satisfactory completion of the study protocol

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Ann Arbor?

Yes, this clinical trial (NCT04992624) has an active research site in Ann Arbor, MI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Osteoarthritis, Knee Treatment Options in Ann Arbor, MI

If you're searching for osteoarthritis, knee treatment options in Ann Arbor, MI, this clinical trial (NCT04992624) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Ann Arbor research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced osteoarthritis, knee specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all osteoarthritis, knee clinical trials near you to find additional studies recruiting in your area.

Osteoarthritis, Knee Clinical Trial in Ann Arbor, MI

Expert Care in Ann Arbor

IRB Approved

No-Cost Care

Apply for This Ann Arbor Location

Why Participate?

Simple Process